Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN) said on Friday it would acquire Amicus Therapeutics (FOLD) for about $4.8 billion, expanding its presence in rare metabolic diseases.
The drugmaker will pay $14.50 per share for Amicus, a premium of 33.1% to the stock's last close. Shares of Amicus surged 30%, while BioMarin rose nearly 5% in premarket trading.
The deal strengthens BioMarin's portfolio with Amicus' approved genetic disorder treatments including Galafold, an oral drug for Fabry disease, which is caused by a faulty gene that leads to a buildup of fatty substances in cells.
Amicus also markets a combination therapy Pombiliti and Opfolda for Pompe disease, a genetic condition in which a complex sugar called glycogen builds up in the body's cells.
Amicus also has U.S. rights to DMX-200, a potential treatment of a type of kidney disease known as focal segmental glomerulosclerosis.
BioMarin intends to finance the deal through a combination of cash on hand and about $3.7 billion of non-convertible debt financing.
The company's total cash and investments at the end of September 30 were about $2 billion.
The acquisition, which is expected to close in the second quarter of 2026, will add revenue immediately after the transaction closes, BioMarin said.
The deal is also expected to add to adjusted profit in the first 12 months after close and be substantially accretive beginning in 2027, the company said.
(Reporting by Christy Santhosh and Sriparna Roy in Bengaluru; Editing by Leroy Leo and Maju Samuel)
LATEST POSTS
- 1
German petrol stations hike prices as once-a-day rule takes effect - 2NASA wants to build a base on the Moon by the 2030s – how and why it plans to build up to a long-term lunar presence
- 3Remain Fit and Sound with These Exercise Fundamentals
- 4100 new alien worlds: Scientists find hidden haul in data from NASA exoplanet-hunting spacecraft
- 5Russian authorities threaten WhatsApp with total ban
- The 15 Most Powerful Forerunners in Business
- Gaza receiving over 70,000 cubic meters of water per day, COGAT claims
- First foreign troop in new gang suppression force lands in Haiti to replace previous mission
- Artemis II astronauts say they're "ready to go" for moon launch
- Moon rocket and weather are on NASA's side for the first astronaut launch in decades
- The Land Rover Freelander Is Back—But It’s No Longer a Land Rover
- Hoist Your Style: Famous Hairdos for Ladies
- The Best 15 Applications for Efficiency and Association
- Rick Steves' Newest Guidebook Is A Fresh Perspective On Italy Spilling The Country's Secrets
